A Founder's Guide to Biotech Funding

Getting a biotech funded takes years, and the process has a specific shape. Your science and your investor narrative have to move together, and the team has to be able to hold both. When any of those drift apart, rounds stall regardless of the data.

This guide maps that process from the beginning: what needs to be in place before you ever pitch, what investors evaluate at each stage, how due diligence has changed, and what separates companies that close biotech funding rounds from those that can't.

"The biggest mistake I see founders make is treating each funding round as a discrete event rather than a continuous narrative," says David H. Crean, PhD, founder and managing partner of Cardiff Advisory LLC, a boutique strategic, corporate finance, and acquisitions advisory firm. "The story you tell at seed has to be architected to survive phase two data even if the science pivots."

The Groundwork Investors Expect to See

Before a pitch deck matters, investors need to see two things: a credible team and defensible intellectual property.

"The first—and arguably most critical—step is assembling the right management team," says Carter Caldwell, MBA, entrepreneur, investor, and Penn Medicine Co-Investment Program Director at the University of Pennsylvania. "In biotech, capital follows leadership. Without a credible, experienced team, it is very difficult to attract institutional capital."

IP comes right behind it. Without exclusivity on your core assets, there is no durable product and no compelling reason for an investor to back you over the next company working in the same space.

"There is no biotech company without a product, and there is no durable product without defensible IP," Caldwell says. "Investors need confidence that the core assets are protected, that freedom to operate has been thoughtfully considered, and that the IP estate can support long-term value creation."

Crean puts it directly: "Most first-timers think biotech is about picking the right drug. It's actually about picking the right team to navigate a decade of uncertainty. Investors invest in people, first and foremost."

The Milestones That Move the Risk-Reward Profile

Investors don't deploy capital uniformly across a biotech's lifecycle. They time it to specific inflection points that shift the company's risk-reward profile. Understanding those inflection points tells you what you need to achieve before the next round is realistic.

Caldwell maps the major inflection points in sequence: locking in a credible CEO and management team; securing the IP estate; generating compelling preclinical data; raising seed or Series A; filing an IND; opening clinical trial sites; dosing the first patient. Each one shifts the risk-reward calculus and opens the door to the next conversation with capital.

"Each of these events meaningfully shifts the risk-reward profile of the company and subsequently opens the door to further investment and advancement," he says. "Investors time capital deployment to coincide with these milestones to balance valuation, risk mitigation, and upside potential."

For founders, this means thinking about milestones not just as scientific goals but as value-creation events. Each one should be planned with the next investor conversation in mind.

The Founder's Job Changes as the Company Advances

Early on, the founder's job is proving the biology is real and building the data story that convinces a skeptical investor there is something worth backing. That means generating proof-of-concept data strong enough to support an IND-enabling package, and framing it in terms an investor can act on.

"For most investors, their natural inclination is to say no first and foremost," Crean says. "You're going to have to build up a very compelling message based on scientific proof that you're on to something and that there's a real market need."

Once that foundation exists, the mindset has to shift. The question is no longer just whether the science works; it is whether the company is hitting the milestones that drive valuation.

"You have to start thinking more about value inflection, not just scientific progress," Crean says. "You have to think about how you look at phase one studies and phase two studies, and how to start staging your investment and your spending against those milestones."

By late-stage development, the skills required change again. Most scientific founders are not built for commercialization. The ones who see that gap coming, and plan for it, build better companies than the ones who don't.

"Most CEOs are coming in as a scientific founder and they primarily think about the science," Crean says. "By then you might need a totally new CEO."

Regulatory Strategy Is Not an Afterthought

One of the most common mistakes early-stage founders make is treating FDA strategy as something to figure out after the phase two data comes in. Investors who have seen companies make this mistake will push hard on regulatory preparedness in due diligence.

"FDA strategy can't be an afterthought," Crean says. "It has to be designed upfront, in terms of your pivotal trial. You have to think about the end game and then work your way back."

This includes knowing what you have agreed with the FDA on, how the competitive landscape may shift during your development timeline, and how your regulatory pathway intersects with your payer strategy. (verify: founders may want to confirm current FDA engagement expectations for their specific therapeutic area, as the regulatory environment has been in flux)

Payer Strategy: The Leg Most Founders Miss

A drug that wins FDA approval but fails to secure reimbursement never reaches patients, and investors know it. Safety and efficacy get you to approval. They don't get you to market. Payer strategy needs to be built into the plan from day one, not retrofitted after the pivotal trial locks.

"A lot of drug developers don't know anything about pricing or don't even focus on anything other than safety and efficacy," Crean says. "You see certain drugs winning FDA approval, but they lose commercial traction because no one's thinking about the reimbursement argument before all the pivotal trial data has been locked."

The related question is patient identification: who exactly are you treating, and how will you find them? For many programs, this is inseparable from companion diagnostic strategy.

"How is that going to weave in with the therapeutic modality that you're going after?" Crean says. "That's ultimately going to help identify the patients who are going to benefit the most."

The Due Diligence Bar Has Moved

Due diligence used to run three to four months. It now routinely runs six to nine, and the scrutiny has deepened. More capital chasing biotech financing has not made it easier to raise; it has made it easier for investors to be selective.

"Due diligence really represents what I would call the floor. It's not the ceiling," Crean says.

Investors are now scrutinizing regulatory strategy, real-time competitive intelligence, and how the leadership team handles adversity. What a team does when phase two data comes in negative tells an investor far more than what it does when the data is clean.

"Anyone can run a company when the data comes in super clean and everyone's celebrating," Crean says. "But what about when things don't go as planned, when the phase two data misses, and now you only have six months of cash?"

What Biotech Financing Actually Requires

Crean distills fundability to six things: team, data, traction, market, IP, and valuation. All six need to be in line. A strong team with weak data, or strong data with an uncalibrated valuation, stalls rounds.

On market: investors want to know whether the condition is underserved and whether the addressable market is large enough to generate a meaningful return. Crean uses a simple frame for IP and differentiation.

"Are you creating a painkiller, or are you creating a vitamin?" he says. "If you're creating a vitamin, it's just not interesting enough for an investor. They want to see you going after a painkiller—meaning there's a problem out there, and you're trying to solve it."

Valuation is where many scientific founders lose investors they could have closed. The cap table math has to be calibrated to market comparables. Asking for a check that implies an outsized valuation, regardless of the science, will end the conversation.

Crean says every founder needs to be able to answer three questions in the room: What do you do? Why should an investor care? How are you going to generate a return?

"Fundable companies have one thing in common—the founder can speak fluently in both the language of science and the language of capital," Crean says. "When those two vocabularies don't connect, the best science in the world dies in a series A or B."